CRVO logo

CERVOMED INC

CRVONASDAQ
πŸ† #4511 by market capEarnings Mar 12US Equity
$1.46β–² $0.13 (+9.77%)
Market closed Β· at close
πŸ””
Track CRVO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 9.8%
7dβ–Ό 12.8%
14dβ–² 3.5%
30dβ–Ό 37.1%
ytdβ–Ό 81.3%
1yβ–Ό 83.6%
🏦Market Cap
$22M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-99.8%
Declining
πŸ“ŠGross Margin
-230.4%
Thin
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
10.2x
Elevated
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.42 – $1.62
52-Week Range
$1.27 – $10.00
Volume (shares)
1,198,341
Avg Volume (shares)
β€”
Shares Outstanding
15.1M
Next Earnings
2027-03-12

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
10.2x
EPS (TTM)
$-2.77
Dividend Yield
β€”
Dilution (1yr)
+6.3%
CRVO logo

CERVOMED INC

CRVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$28Mβ–² +55.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$23Mβ–² +41.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.3Mβ–² +6.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ–Ό βˆ’$764K YoY
StockOtter Β· stockotter.space

About CERVOMED INC

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·6d ago

CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage

GlobeNewsWireΒ·13d ago

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Presentation and publication of clinical and biomarker data, regulatory developments,Β  and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies Rapidl

GlobeNewsWireΒ·24d ago

CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB

BenzingaΒ·Oct 12

CervoMed Shows Progress in Treating Rare Aphasia Condition

CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).

Defense WorldΒ·Oct 5

CervoMed (NASDAQ:CRVO) Earns β€œBuy” Rating from HC Wainwright

CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Monday, MarketBeat reports. A number of other brokerages have also weigh

Defense WorldΒ·Oct 3

CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of β€œModerate Buy” from Brokerages

CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the